89Zr immuno-PET: Comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies

Journal of Nuclear Medicine

Volumn 44, Issue 8, 2003, Pages 1271-1281

  Verel, Iris ^a   Visser, Gerard W M ^b   Boellaard, Ronald ^a   Walsum, Marijke Stigter Van ^a   Snow, Gordon B ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

89Zr; PET; Radioimmunoconjugates; Tumor detection; Xenograft bearing nude mice

Indexed keywords

CARBOPROST METHYL; DEFEROXAMINE; FERRIC ION; HYDROXAMIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CARBOPROST METHYL N SUCCINIMIDE DESFERRIOXAMINE ZR 89; PHENOL DERIVATIVE; SUCCINIMIDE; SULFIDE; TETRAFLUOROPHENOL; UNCLASSIFIED DRUG; YTTRIUM; ZIRCONIUM; DIAGNOSTIC AGENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CHELATION; CHEMICAL REACTION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; EVALUATION; HEAD AND NECK CANCER; HUMAN; IMMUNOREACTIVITY; INSTRUMENTATION; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYNTHESIS; TIME SERIES ANALYSIS; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG STABILITY; FEASIBILITY STUDY; FEMALE; ISOLATION AND PURIFICATION; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; METHODOLOGY; NUDE MOUSE; RADIOIMMUNOASSAY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; VALIDATION STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG STABILITY; FEASIBILITY STUDIES; FEMALE; HUMANS; ISOTOPE LABELING; LUNG NEOPLASMS; MICE; MICE, NUDE; ORGAN SPECIFICITY; RADIOIMMUNODETECTION; RADIOISOTOPES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; ZIRCONIUM;

EID: 0141669355     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Goldenberg DM, Larson SM, Reisfeld RA, Schlom J. Targeting cancer with radiolabeled antibodies. Immunol Today. 1995;16:261-264
2. DeNardo SJ, Kroger LA, DeNardo GL. A new era for radiolabeled antibodies in cancer? Curr Opin Immunol. 1999;11:563-569.
3. 99mTc-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res. 1995;1:591-598.
4. 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med. 2000;41:1999-2010.
5. Sowby FD, ed. Radionuclide Transformations: Energy and Intensity of Emissions. ICRP publication 38, vol 11-13. Oxford, England: Pergamon Press; 1983:44, 58, 79, 205, 217, 218, 668.
6. Meijs WE, Herscheid JDM, Haisma HJ, Pinedo HM. Evaluation of desferal as a bifunctional chelating agent for labelling antibodies with zirconium-89. Appl Radiat Isot 1992;43:1443-1447
7. Meijs WE, Haisma HJ, Klok RP, et al. Zirconium-88/89 labelled monoclonal antibodies: distribution in tumour-bearing nude mice. J Nucl Med. 1997;38:112-118.
8. Lewis MR, Shively JE. Maleimidocysteineamido-DOTA derivatives: new re-agents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjug Chem 1998;9:72-86.
9. 186Re using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med. 1993;34:1953-1963.
10. Vrouenraets MB, Visser GWM, Stigter M, Oppelaar H, Snow GB, van Dongen GAMS. Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy. Cancer Res. 2001;61:1970-1975.
11. 88Y reactions up to 40 MeV Physical Review C. 1988;38:1624-1637.
12. Meijs WE, Herscheid JDM, Haisma HJ, et al. Production of highly pure no-carrier-added zirconium-89 for the labelling of antibodies with a positron emitter. Appl Radiat Isot. 1994;45:1143-1147.
13. Herscheid JDM, Hoekstra A, Vos C N-succinyldesferrioxamine B: a potential radiopharmaceutical for assessing renal function. Eur J Nucl Med. 1984;9:508-510.
14. Monzyk B, Crumbliss AL. Factors that influence siderophore-mediated iron bioavailability: catalysis of interligand iron(III) transfer from ferrioxamine B to EDTA by hydroxamic acids. J Inorg Biochem 1983;19:19-39.
15. Vis RD, Kramer JLAM, Tros GHJ, van Langevelde F, Mars L. The upgraded Amsterdam nuclear microprobe. Nucl Instrum Methods Phys Res B. 1993;77:41-44.
16. Van Gog FB, Visser GWM, Stroomer JWG, Roos JC, Snow GB, van Dongen GAMS. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions Cancer. 1997;80:2360-2370.
17. Hermsen MAJA, Joenje H, Arwert F, et al. Centromeric breakage as a major cause of cytogenetic abnormalities in oral squamous cell carcinoma. Genes Chromosomes Cancer. 1996;15:1-9.
18. Guide for the Care and Use of Laboratory Animals. Washington, DC: Government Printing Office, 1985. NIH publication 86-23.
19. Pelegrin A, Folli S, Buchegger F, Mach JP, Wagnieres G, van den Bergh H. Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. Cancer. 1991;67:2529-2537.
20. Kukis DL, DeNardo GL, DeNardo SJ, et al. Effect of the extent of the chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res. 1995;55:878-884.
21. Van Gog FB, Visser GMW, Klok R, van der Schors R, Snow GB, van Dongen GAMS. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics. J Nucl Med. 1996;37:352-362.
22. 67Ga-Labeled antibodies for immunoscintigraphy and evaluation of tumor targeting of drug-antibody conjugates in mice Cancer Res. 1988;48:1189-1194.
23. Pochon S, Buchegger F, Pelegrin A, et al. A novel derivative of the chelon desferrioxamine for site-specific conjugation to antibodies. Int J Cancer. 1989; 43:1188-1194.
24. Arano Y, Inoue T, Mukai T, et al. Discriminated release of a hippurate-like radiometal chelate in nontarget tissues for target-selective radioactivity localization using pH-dependent dissociation of reduced antibody. J Nucl Med 1994;35 326-333.
25. Chakrabarti MC, Le N, Paik CH, De Graff WG, Carrasquillo JA. Prevention of radiolysis of monoclonal antibody during labeling J Nucl Med. 1996;37:1384-1388.
26. 131I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. J Nucl Med. 2001;42:509-519.
27. 90Y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid. Bioconjug Chem. 2001;12:554-558.
28. Wu AM, Yazaki PJ, Tsai S, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci 2000;97:8495-8500.
29. 124iodine in patients with breast cancer. Int J Cancer. 1991;47:344-347.
30. Larson SM, Pentlow KS, Volkow ND, et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med. 1992;33:2020-2023
31. 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med. 2001;42:764-769
32. Eary JF. PET imaging for planning cancer therapy. J Nucl Med. 2001;42:770-771.